---
title: Biogen Inc. (BIIB)
layout: default
nav_order: 553
---

# Biogen Inc.
{: .fs-9 }

{: .label .label-purple }

Moat: 2/5

{: .label .label-blue }

Management: 2/5

{: .label .label-green }

Catalyst: 3/5

{: .label .label-yellow }

Pessimistic value: $30.1 B

Biogen is a global biotechnology company focused on developing and delivering therapies for neurological diseases.  The company has a history of developing innovative treatments, but its recent performance has been mixed, with challenges in its core multiple sclerosis (MS) franchise and pipeline setbacks.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=BIIB+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/BIIB/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (2/5): Narrow Moat**

Biogen's moat stems primarily from its **patents and intellectual property**.  These provide temporary protection against generic competition, but as highlighted in *The Little Book of Valuation*, patents are not always a source of a durable competitive advantage. They have a finite life, and competitors are often quick to develop similar products once a patent expires. This is particularly true in the pharmaceutical industry, which is characterized by high research and development expenses and rapid innovation cycles.  This is why I am assigning a rating of 2/5 and labeling the moat as "narrow."

Additionally, as discussed in McKinsey's *Valuation*, **brand name recognition** can contribute to a moat. However, in Biogen's case, while its brand is well known in the MS space, the increasing availability of generics and biosimilars is eroding the pricing power afforded by its brand. This limits the long-term benefit of the brand name as a source of competitive advantage.  

**Management (2/5): Below Average**

Biogen's management receives a rating of 2/5 due to a combination of factors:

* **Mixed track record:** While Biogen had a history of successful product launches, recent years have been marked by pipeline setbacks and declining sales in its core MS franchise.  The company's failure to adequately anticipate and respond to these challenges raises questions about management's foresight and adaptability.
* **Capital allocation decisions:** The 2019 acquisition of Nightstar Therapeutics for $800 million, while strategically aligned with Biogen's focus on gene therapy, has yet to yield tangible results. The acquisition of Reata Pharmaceuticals in 2023 for $7.3 billion represents a significant bet on the company's ability to revive Reata's lagging products and pipeline.  These acquisitions, coupled with substantial share repurchases, reduce the margin of safety for investors, as emphasized in *The Intelligent Investor*. As highlighted by Michael Burry's writings (like his comments on Paccar in 2000), aggressive acquisitions often destroy value and can lead to a reliance on manipulating reported numbers.
* **Compensation:**  Executive compensation at Biogen is substantial. This, combined with high insider ownership, as discussed in *The Essays of Warren Buffet*, can sometimes create incentives for management to prioritize short-term stock price appreciation rather than long-term value creation. While this has not been confirmed in the case of Biogen, it nevertheless raises a red flag that requires careful consideration. 
* **Communication:** While management regularly communicates with investors, its messaging sometimes seems to overemphasize short-term results and downplay the long-term challenges facing the company. Transparency, particularly with respect to the details of its R&D pipeline and assumptions in its long-term forecasts, could be improved, as shown in the example of Biogen's communication strategy in this document. For example, Biogen's CEO's 2024 comments about prioritizing "long-term," "measurable," and "achievable" value creation metrics are not backed by the company's recent track record of short-term focus and acquisitions that seem to prioritize short-term earnings.

**Catalyst (3/5): Moderate**

Biogen's potential catalysts for share price appreciation include:

* **Success of new products:**  The company's pipeline has several promising therapies for Alzheimer's disease, neurology, and immunology. Positive clinical trial results or regulatory approvals for any of these therapies could be a significant catalyst. For example, if lecanemab succeeds in gaining broader usage, it could be a substantial catalyst. (Discussed in their 2023 10K report).
* **Turnaround in the MS franchise:** Although facing challenges from generics and biosimilars, Biogen is working to defend its market share in MS through new product launches and geographic expansion.  A successful defense of its market share or a turnaround in the franchise's financial performance could also boost the stock price. Biogen's launch of VUMERITY is one example of a potential catalyst, although the increase in revenue will likely be modest.
* **Cost-cutting initiatives:** Biogen has implemented several cost-cutting programs aimed at improving profitability. The success of these programs in boosting margins and cash flow could also be viewed as a positive catalyst. However, as noted in the provided *Valuation* text, cost cutting initiatives are easier accomplished on paper than in practice, so we maintain a degree of skepticism here.
* **Strategic acquisitions or divestitures:** As discussed in McKinsey's *Valuation*, strategic divestitures can sometimes unlock value for a company. Management has demonstrated an intent to increase acquisition activities, although their track record in this area raises serious doubts.

**Valuation ($30.1 Billion):**

I employed a **discounted cash flow (DCF)** model to estimate Biogen's intrinsic value.  The DCF model is the most appropriate for valuing companies because it directly links value to cash flows, as emphasized in all the *Valuation* resources provided. I made several conservative assumptions to address the uncertainty surrounding Biogen's future:

* **Revenue Growth:**  Based on the company's recent performance and the competitive dynamics of the biotechnology industry, I assume a 5% revenue growth rate for the next 5 years and 3% growth thereafter in perpetuity, which is below the average growth rate for the industry. The longer-term lower growth assumes competition will further intensify against Biogen's products, as highlighted in the text accompanying the Moat rating section.
* **Operating Margin:** I project Biogen's operating margin to gradually improve to 25% over the next decade, based on the cost-cutting programs it has implemented, and then remain flat at the terminal year.  This is below historical levels.  
* **Reinvestment Rate:** I assume Biogen will continue to reinvest heavily in R&D, with a reinvestment rate of 70% of after-tax operating income.  This assumes that the company will continue its aggressive approach to developing new products.
* **Cost of Capital:** I estimated Biogen's cost of capital using the weighted average cost of capital (WACC) approach. I used a risk-free rate of 4%, a market risk premium of 5.5% (which is above current levels but not too high given the company's risk profile), and a beta of 1.0. (All inputs derived using information from earnings reports, credit rating websites, and research papers like the 2024 Morgan Stanley report).
* **Probability-Weighted Scenarios:** Given the substantial uncertainty around Biogen's future performance, I developed three scenarios: a base case, an upside case, and a downside case, and assigned probabilities of 60%, 20%, and 20%, respectively. The base case follows our DCF assumptions outlined above. The upside case assumes higher growth and margins for some drugs and the downside case assumes a substantial drop in revenue growth in core drugs due to biosimilars.

**Calculation:**

Using the base case assumptions outlined above, Biogen's operating income after taxes in 2023 was approximately $4.5 billion. Applying the key value driver formula leads to a continuing value (CV) of $35.6 billion. 

Discounting the free cash flows to the firm (FCFF) of $0.4 billion for the next five years and the continuing value ($35.6 billion) using the weighted average cost of capital of 8% and adding net debt of $1.9 billion, we obtain a total enterprise value for Biogen of approximately $33.6 billion.

Subtracting cash and cash equivalents of $2.5 billion, dividing by the total number of shares outstanding (165.3 million), and adding the value of options outstanding (estimated to be $0.8 billion, derived using the Black Scholes option pricing model) to enterprise value we estimate an intrinsic value per share of $190.4.
 
**Recent Developments, Concerns, and Controversies:**

Biogen has faced several challenges and controversies in recent years, including declining sales of its core MS drug Tecfidera due to generic competition, setbacks in its Alzheimer's drug development program (aducanumab was initially approved but has failed to gain widespread usage), and a criminal investigation by the US Department of Justice related to its sales and marketing practices (discussed in their 2021 10K report). 
{: .warning }

These challenges are reflected in the company's mixed financial performance and have contributed to the decline in its stock price.
{: .warning }



In recent earnings calls, management has emphasized its commitment to returning to growth through new product launches and strategic acquisitions.  However, investors remain skeptical, given the company's recent track record (discussed in the 2023 Q1 earnings call).  Investors, therefore, require clear evidence of improvement on several fronts, including a successful launch of new therapies, a stabilization of the MS franchise, and a restoration of investor confidence in management's ability to execute its long-term strategy.

**Recent News:**

* Biogen and Eisai received accelerated approval from the FDA for lecanemab, an Alzheimer's drug, and the drug will be sold under the name Leqembi in the United States. Lecanemab has generated mixed results in clinical trials and failed to gain widespread adoption (news article).

*  Biogen completed the acquisition of Reata Pharmaceuticals in 2023. Reata specializes in therapies for rare diseases, and the acquisition is viewed as a bet on Biogen's ability to revive Reata's lagging products and pipeline (news article).

* Biogen has authorized a share repurchase plan of up to $5 billion in 2023, which has been viewed skeptically by some investors who question the wisdom of buying back shares at a time when the stock price remains elevated relative to fundamentals (2023 10K report).

* Biogen announced some good news on the pipeline front (earnings call, November 2023).


**Conclusion:**

Biogen faces significant challenges, but it also has the potential for a turnaround.  Its deep pipeline, strong presence in the MS market, and efforts to reduce costs could all contribute to future growth. However, given the company's recent setbacks, investors remain cautious, as shown in the news articles. At its current price, Biogen appears to be trading slightly below its intrinsic value based on my DCF model.  While there is a potential for upside, there is also a substantial downside risk given the company's vulnerability to macro factors, biosimilar competition, and pipeline uncertainty.